Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients  by unknown
Chapter 2: Lifestyle and pharmacological treatments
for lowering blood pressure in CKD ND patients
Kidney International Supplements (2012) 2, 347–356; doi:10.1038/kisup.2012.52
INTRODUCTION
This section outlines lifestyle and pharmacological methods
to reduce BP in patients with non-dialysis-dependent CKD
(CKD ND). Because these strategies were covered in detail in
the 2004 KDOQI Clinical Practice Guidelines on Hypertension
and Antihypertensive Agents in Chronic Kidney Disease (http://
www.kidney.org/professionals/KDOQI/guidelines_bp/index.
htm),1 we concentrate on issues relating to BP control in
CKD patients that have arisen since 2004. Additional
information that may be of help to the clinician (although
not specifically relevant to CKD patients) can be found in the
Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure
(JNC 7) (http://www.nhlbi.nih.gov/guidelines/hypertension/
jnc7full.pdf).9
GENERAL STRATEGIES
It is generally accepted that a stepwise combination of
lifestyle modifications and drug therapy should be used to
lower BP in CKD patients, with escalation of efforts
depending on factors such as the severity of the BP elevation,
the co-morbidities present and the age of the patient.
2.1: Individualize BP targets and agents according to age,
co-existent cardiovascular disease and other co-
morbidities, risk of progression of CKD, presence
or absence of retinopathy (in CKD patients with
diabetes) and tolerance of treatment. (Not Graded)
RATIONALE
We recognize that individual decision making is required
regarding BP targets and agents with the risks and benefit
being taken into consideration; however, since there is little
evidence from RCTs to guide these decisions, this recom-
mendation has not been graded.
The potential benefits of lower BP include a decreased risk
of both CVD and progression of CKD. To assess the likely
benefit in a given patient, the clinician needs to consider such
issues as the prior rate of CKD progression, the expected course
of the specific disease, the level of urinary albumin excretion
and the presence or absence of other risks of CVD. Potential
adverse effects generic to treatment used to lower BP include
decreases in cerebral perfusion (contributing to dizziness,
confusion and falls) and acute deterioration in kidney function.
It is widely acknowledged that achievement of a reduction
in BP can be difficult in CKD patients, particularly in the
elderly, those with co-morbidities, and those with diabetes
mellitus.1,9,30 Increased conduit-artery stiffness, resulting in
high pulse pressure (with high systolic and low diastolic
pressures) is common in CKD patients, the elderly and
patients with diabetes.31–36 Arterial stiffening is associated
with an increased risk of CVD independent of other
recognized risk factors.37–39 With a high pulse pressure,
efforts to reduce systolic BP in older patients and those with
coronary artery disease (CAD) can result in lowering
diastolic BP to levels well below diastolic targets, which
may be associated with greater morbidity or mortality.40,41 A
J-shaped relationship between achieved BP and outcome has
been observed in the elderly and in patients with vascular
disease, possibly suggesting that BP can be reduced too far in
these patients.40,42,43 Discussion of this issue is further
elaborated in Chapters 7 and 8. Unfortunately, in CKD
patients, the available evidence proved to be insufficient to
allow the Work Group to define the lowest BP targets (see
Chapter 8).
Similarly, when considering the choice of BP-lowering
agents, decision making should be tailored to the individual
patient. For instance, ACE-Is and ARBs are potentially
harmful in the presence of significant renovascular disease or
volume depletion, or when used in combination with
nonsteroidal anti-inflammatory drugs (NSAIDs) or cycloox-
ygenase-2 (COX-2) inhibitors (as outlined later in this
chapter). The presence of diabetic retinopathy in a CKD
patient may also influence BP target and choice of agent as
outlined in Chapter 4.
Based on these considerations, the Work Group concluded
that it is good clinical practice to assess the risks and benefits
of BP-lowering treatment in an individual patient and to
tailor therapy accordingly.
2.2: Inquire about postural dizziness and check for
postural hypotension regularly when treating CKD
patients with BP-lowering drugs. (Not Graded)
RATIONALE
Patients with CKD, particularly the elderly31 and diabetic
patients with autonomic neuropathy, are prone to orthostatic
hypotension,44,45 which may be exacerbated by volume
depletion. Many CKD patients will require combinations of
drugs to control BP including vasodilators, which can cause
or exacerbate postural hypotension. This can lead to postural
dizziness, reduced adherence and in extreme cases, syncope
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or falls with consequent injury. Accordingly, it is sensible to
regularly check for symptoms of postural dizziness and to
compare lying, sitting and standing BP in CKD patients,
particularly before and after altering the treatment regimen.
LIFESTYLE MODIFICATION
The impact of lifestyle-related factors on BP and the risk of
cardiovascular and other diseases have been well documented.
A number of observational studies in the general population
have linked factors such as salt intake,46 weight and body mass
index (BMI),47 exercise frequency,48 and alcohol intake49 with
BP level. RCTs addressing many of these factors have been
undertaken, the results of which have led the authors of BP
guidelines for the general population9 (e.g., JNC 7) to make
specific recommendations about the management of lifestyle as
a key component of BP management.
Individuals with CKD generally have higher9 BP levels
than people with normal kidney function and their BP may
be particularly sensitive to some factors related to lifestyle.
For example, high salt intake may potentially have a greater
impact on BP in patients with CKD than in those without
CKD since CKD may reduce the ability to excrete the salt
load in the urine. CKD patients may also be more sensitive
to harms related to lifestyle interventions; for instance, an
individual with tubular disease with salt wasting from the
kidney could be at increased risk of hypovolemia if salt
intake is restricted. Furthermore, some potential lifestyle
interventions, such as increased physical exercise, may be
difficult for patients with CKD owing to reduced energy
levels.
Lifestyle modification offers the potential to lower BP in a
simple, inexpensive, effective fashion while also improving a
range of other outcomes (e.g., changes in lipid levels
resulting from diet and exercise and liver function through
moderation of alcohol intake). Because lifestyle changes are
applicable to the general population and are potentially
implementable at low expense worldwide, the Work
Group felt many were sufficiently important to warrant an
evidence grade of level 1, with the strength of the evidence
varying in accordance to their potential to do harm in CKD
patients.
2.3: Encourage lifestyle modification in patients with
CKD to lower BP and improve long-term cardio-
vascular and other outcomes:
2.3.1: We recommend achieving or maintaining a
healthy weight (BMI 20 to 25). (1D)
RATIONALE
K Weight reduction lowers BP in the general population.
K Observational studies show that weight-loss strategies
reduce BP in CKD patients.
K Weight-reduction strategies may result in other health
benefits to CKD patients including reduction in urine
albumin or protein levels, improved lipid profile and
increased insulin sensitivity.
The prevalence of obesity is very high in Western countries
and is increasing rapidly in developed and developing
countries around the world. A strong relationship exists
between body weight (usually defined as BMI) and BP levels
in the general population.50–52 Compared with a person of
normal weight, individuals who are overweight or obese tend
to have higher BP levels, abnormalities in a range of other
cardiovascular parameters (e.g., dyslipidemia52), and an
increased risk of cardiovascular events.
Weight and BP. A weight-reducing diet has been clearly
demonstrated to lower BP in overweight individuals in the
general population. A systematic review53 published in 2006
identified 14 trials assessing the effects of dietary modification
on BP in the general population, all but two of which assessed
the effects of weight reduction in overweight persons. Many of
the 14 trials also included other modifications to diet (e.g.,
increased fruit and vegetable intake and salt reduction) and
lifestyle (e.g., increased exercise). Trials were 8 to 52 weeks in
duration and mostly included participants with elevated BP
levels. The quality of the trials was generally suboptimal.
Overall, dietary modification reduced systolic BP by
6.0mmHg (95% confidence interval [CI] 3.4–8.6) and
diastolic BP by 4.8mmHg (95% CI 2.7–6.9). High levels of
heterogeneity in the trial results were observed.
The available data regarding the effects of weight loss in
CKD patients has been systematically reviewed by Nava-
neethan et al.54 Only two randomized trials were identified
but 11 observational studies were also included. A range of
surgical and non-surgical weight-loss interventions were
assessed. All interventions, when taken together, resulted in
significant reduction in weight among CKD patients. This
was associated with a reduction in urinary protein excretion
(described in two studies) but no overall effect on the GFR,
possibly due to the short term nature of the studies. Effects
on BP were not reported in the RCTs, whereas the
observational studies reported consistently large, significant
reductions in BP compared to baseline with both non-
surgical weight loss (weighted mean difference in BP
9.0mmHg; 95% CI 3.7–14.2mmHg; Po0.0001) as well as
surgical weight loss (weighted mean difference, 22.6mmHg;
95% CI 19.1–26.2; Po0.0001). Thus, weight loss likely
improves BP in patients with CKD, although high-quality
RCTs are needed to confirm this finding.
Body weight and outcomes. In the general population,
overweight and obesity have been clearly shown to be
associated with an increased risk of cardiovascular events and
death.52 A J-curve relationship has been described in many
reports, revealing an increased risk in underweight individuals
(e.g., those with a BMI o18.5) as well. RCTs have demon-
strated that weight loss reduces the incidence of diabetes,55 but
any beneficial effects on cardiovascular outcomes or survival
remain to be proven. Indeed, a number of RCTs involving use
of pharmacological agents to induce weight loss have been
stopped early owing to unintended and unanticipated adverse
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effects of the agent being assessed (e.g., rimonabant and
sibutramine).56,57
The data are less clear for patients with CKD. Obesity has
been proposed as a possible potentiator of CKD progression;
however, reliable data remain sparse. Many observational
studies have suggested that among patients with advanced
CKD who are dialysis-dependent, and particularly hemodia-
lysis-dependent, clinical outcomes might actually be better
for overweight individuals than for non-overweight indivi-
duals.58,59 Other studies have reported conflicting results.60 It
is possible that these observations are due to reverse causality,
with the results driven by underlying malnutrition or
inflammation in the lower-weight patients and they may
also reflect differences in the proportions of muscle and fat in
patients with CKD compared with people without CKD.
These data should therefore be interpreted with caution.
For overweight individuals, the method used to reduce
body weight may be important within the context of CKD.
Popular and widely recommended weight-loss diets are
commonly high in potassium and protein and may therefore
increase risks of hyperkalemia and CKD progression in
patients with CKD. As the potential benefits and harms have
not been specifically addressed in the CKD population, the
use of these diets is not recommended.
Overall, the available data suggest that achieving or
maintaining a body weight in the healthy range will lead to
improved BP levels and better long-term CKD outcomes.
This is particularly clear for individuals with CKD stages 1–2.
Caution should be exercised in patients with more advanced
CKD, because malnutrition may be associated with adverse
outcomes. Since a high weight may be protective in CKD 5D
patients, there could be risks associated with encourag-
ing weight loss in those with advanced CKD. Hence,
Recommendation 2.3.1 was graded 1D.
2.3.2: We recommend lowering salt intake too90mmol
(o2 g) per day of sodium (corresponding to 5 g of
sodium chloride), unless contraindicated. (1C)
RATIONALE
K Lowering salt intake reduces BP in the general population.
K In CKD patients with reduced GFR, salt retention is
associated with an increase in BP.
A relationship between average daily salt intake and BP levels
has long been recognized, leading to calls from the World
Health Organization (WHO) for salt intake to be restricted to
improve BP levels (http://www.who.int/cardiovascular_
diseases/guidelines/Full%20text.pdf).61 Restricting salt intake
clearly lowers BP by a moderate amount, as demonstrated in
a systematic review of seven trials,53 most of which assessed
the impact of restricting salt intake to 4 to 6 g (70–100mmol).
Overall, BP levels were reduced as compared to baseline
levels: systolic BP by 4.7mmHg (95% CI 2.2–7.2) and
diastolic BP by 2.5mmHg (95% CI 1.8–3.3). Moderate
heterogeneity was observed in the effects on systolic BP, but
this was corrected when one outlier trial was excluded. Other
systematic reviews including a different group of trials have
suggested similar but somewhat smaller benefits.62
Alterations in salt handling are likely to be a significant
contributor to elevated BP levels in patients with CKD.
Although no large scale long term RCTs of salt restriction in
CKD patients were found, there is no reason to believe that
BP reductions should not also be observed. Reducing salt
intake could have a greater capacity to lower BP in patients
with CKD who have salt and water retention and this
intervention should be routinely discussed with such
individuals. A low-sodium diet has been shown to further
reduce BP and urine albumin or protein levels in the short
term in patients on ARBs63–66 and may be a consideration
for those with high BP who have a poor response to ACE-Is
or ARBs.
Some forms of CKD may be associated with salt wasting
from the kidney. Affected individuals may be at higher than
usual risk of volume depletion and electrolyte disturbances
potentiated by salt restriction. Volume and electrolyte status
should thus be carefully monitored in patients with CKD
undergoing salt restriction. Recent studies suggesting that low
urinary sodium excretion (hence perhaps low dietary sodium
intake) associates with higher mortality in diabetes have yet
to be confirmed by others or explained.67,68
Since salt restriction is an inexpensive and important
contributor to lowering BP in the generally population
worldwide, this intervention was deemed a level 1 recom-
mendation. But since the evidence base for CKD patients
included only small, short-term RCTs involving special
circumstances, Recommendation 2.3.2 was graded 1C.
2.3.3: We recommend undertaking an exercise program
compatible with cardiovascular health and toler-
ance, aiming for at least 30minutes 5 times per
week. (1D)
RATIONALE
Increased physical exercise has been linked to a broad range
of positive health outcomes through a wide variety of
mechanisms. A clear inverse relationship between exercise
and average daily BP has been demonstrated by a large
volume of previous epidemiological data in the general
population, although exercise may lead to modest and acute
physiological increases in BP during the time of the activity.
The effects of exercise on BP in the context of RCTs have
been systematically reviewed in the general population.53
Most of the 21 RCTs included in the review examined the
efficacy of 3 to 5 weekly sessions of aerobic exercise lasting 30
to 60minutes. Overall, the exercise group had an average
reduction in systolic BP of 6.1mmHg from baseline (95% CI
2.1–10.1) and in diastolic BP of 3.0mmHg (95% CI 1.1–4.9).
The effects were slightly reduced when one outlier trial was
excluded from the analysis (to average reductions of 4.6 and
2.6mmHg, respectively), but moderate heterogeneity among
the results remained.
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No RCTs in the CKD population were found. A post hoc
observational analysis69 of the Modification of Diet in Renal
Disease (MDRD) study population did not identify a clear
relationship between level of physical activity at baseline and
the subsequent risk of death, although trends toward better
outcomes for active individuals were observed. Two larger
studies from the US Renal Data System found that CKD 5D
patients who are sedentary have a higher risk of death than
those who are active.70,71 All of these studies are observa-
tional and more data are required.
The benefits of exercise on BP and on general health appear
likely to be similar in the CKD and the general population,
with no strong rationale for different recommendations. On
this basis, Recommendation 2.3.3 was graded 1D.
2.3.4: We suggest limiting alcohol intake to no more than
two standard drinks per day for men and no more
than one standard drink per day for women. (2D)
RATIONALE
Alcohol has been shown to produce both acute and chronic
increases in BP, suggesting that restricting alcohol intake
would lower BP. In a systematic review of four trials,53
restricting alcohol intake in the general population resulted
in a 3.8mmHg reduction (95% CI 1.4–6.1) in systolic BP and
a 3.2mmHg reduction (95% CI 1.4–5.0) in diastolic BP, with
no evidence of heterogeneity among the results. No data
specific to CKD patients were found, but the effects are
expected to be similar.
Most data suggest that up to two standard drinks per day
for a man and 1 standard drink per day for a woman are likely
to be safe. The definition of a standard drink varies from 8 to
19.7 g of alcohol in different countries (see http://whqlibdoc.
who.int/hq/2000/who_msd_msb_00.4.pdf).72 10 g of alcohol
is equivalent to 30ml of spirits, 100ml of wine, 285ml of full-
strength beer, and 425ml of light beer. The benefits of alcohol
moderation on BP and on general health appear likely to be
similar in the CKD and the general population, with no
strong rationale for different recommendations. On this basis,
Recommendation 2.3.4 was graded 2D.
OTHER INTERVENTIONS
Cigarette smoking. Cigarette smoking and exposure to
environmental tobacco smoke are clearly among the most
potent modifiable risk factors for CVD in the general
population and in patients with CKD. Although it does not
have a clear, direct impact on long-term BP, the avoidance of
exposure to cigarette smoke is a critical aspect of cardiovas-
cular risk reduction but as yet there are no RCTs in the CKD
population.
Dietary supplementation. The effects of potassium sup-
plementation on BP have been assessed in a number of
studies.53 These have produced conflicting results, with some
but not all indicating a benefit. CKD patients often have
reduced capacity for potassium excretion, particularly as the
GFR falls, such that the risk of hyperkalemia may be
increased. In the absence of specific studies demonstrating
a benefit in CKD patients, we cannot recommend potassium
supplementation to reduce BP in patients with CKD.
The evidence base for magnesium supplementation is
similar, with some but not all studies suggesting a benefit
with respect to BP.53,73 Although hypermagnesemia is not a
common problem in CKD patients, magnesium supplemen-
tation cannot be recommended without specific data
demonstrating its safety and efficacy.
Fish-oil supplementation has been shown to produce
small but significant reductions in BP in a number of RCTs
and systematic reviews.53,74 The mechanisms of these effects
remain uncertain, however and the safety of fish oil has not
been clearly demonstrated in CKD patients. Although some
data supporting the use of fish oil exists for patients with IgA
nephropathy,75 it is premature to recommend this treatment
for BP lowering in the CKD population.
BP-LOWERING AGENTS
RCTs involving both CKD and non-CKD populations in which
a target BP has been set at the levels recommended in this
Guideline clearly show that most patients will require two or
more antihypertensive agents to achieve these targets. Surveys
of BP control in CKD patients indicate that three or more
agents are frequently needed. With the exception of ARBs or
ACE-Is in CKD patients with high levels of urinary albumin or
protein excretion, there is no strong evidence to support the
preferential use of any particular agent(s) in controlling BP in
CKD; nor are there data to guide the clinician in the choice of
second- and third-line medications. Since the 2004 KDOQI
Guideline1 was published, there has been an increasing trend
towards tailoring antihypertensive therapy to the individual
patient, taking into account issues such as the presence or
absence of high urine albumin excretion, co-morbidities,
concomitant medications, adverse effects, and availability of
the agents. Ultimately, the choice of agents is less important
than the actual reduction in BP achieved, since BP reduction is
the major measurable outcome in the individual patient.
Other information of value in deciding on the optimal BP
lowering regimen include data on drug half-life and dose
adjustments in CKD stage 5D, which may be of help in guiding
the use of BP lowering drugs in advanced CKD ND.4,76
The optimal timing of administration of medication has
not been studied in CKD patients. CKD patients who do not
have the normal decrease in BP during sleep (non-dippers
and reverse dippers) have worse cardiovascular and kidney
outcomes when compared to dippers.11,12,77–79 Whether the
recently reported strategy of evening dosing to produce
nocturnal dipping will improve outcomes in CKD patients,
as has been described in individuals with essential hyperten-
sion, remains to be established.80–82
The ERT was not asked to search for evidence of
the effectiveness of established anti-hypertensive agents in
lowering BP in patients with CKD, since it is generally
believed that all such drugs are effective, although the
sensitivity in individual patients may vary, as may be the side
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effects. Instead, the ERT focused on two issues. Firstly,
studies that compared different BP targets were identified. In
these studies, only the BP targets were randomized; the
protocols varied with respect to the sequence of drugs and
escalation of dose. Secondly the ERT searched for studies
that included a comparison of different combinations of
anti-hypertensive agents. In these studies, only the choice of
first-line drug was randomized, with study protocols varying
with respect to drug dose, use of concomitant agents and BP
thresholds for drug titration (Table 5, see Methods for
Guideline Development).
The KDOQI Clinical Practice Guidelines on Hypertension
and Antihypertensive Agents in Chronic Kidney Disease (http://
www.kidney.org/professionals/KDOQI/guidelines_bp/index.
htm)1 contains details of clinical pharmacology and practical
guidance on the use of the various agents to lower BP in CKD
patients. Information on CKD- and CVD-related indications,
side effects, dosages and contraindications relevant to all
commonly used anti-hypertensive agents as well as strategies
to improve adherence and warnings regarding the hazards of
certain combinations are also noted therein. The Work
Group believed that there was insufficient new evidence to
warrant rewriting the clear guidance provided in the KDOQI
Guideline. However, at the request of the KDIGO Board, the
Work Group summarize specific aspects of the use of
antihypertensive agents in CKD patients. We outline the
information that can be drawn from the known pharmacol-
ogy of agents or observations in non-CKD patients,
emphasizing the difficulty in extrapolating to CKD patients,
especially those with advanced CKD.
Given that the prescribed drug regimen commonly
involves many medications, it is reasonable to use strategies
that might maximize the likelihood of adherence, including
the use of cheaper drugs, convenient frequency of dosing
and reduction in pill numbers. This can be achieved by
prescribing once-daily medication and combination pills
(which are simpler to take and in some circumstances may be
less expensive than the individual agents) when possible.83
Renin–angiotensin–aldosterone system blockers
Because of its pivotal role in regulation of BP, the RAAS
system is an obvious target for BP-lowering medications.
Although other agents, particularly beta-blockers, interfere
with the RAAS pathway, the main RAAS inhibitors are
ACE-Is, ARBs, aldosterone antagonists, and DRIs.
ACE-Is and ARBs. ACE-Is block the conversion of angio-
tensin I to angiotensin II and the degradation of bradykinin. It
seems likely that the accumulation of bradykinin leads to
persistent dry cough, a recognized side effect which occurs in
5 to 20% of patients on ACE-Is. Angioneurotic edema can
occur with both ACE-Is and ARBs, although the relative
frequencies and the mechanism are not clear. ARBs act by
competitively antagonizing the interaction between angioten-
sin II and angiotensin receptors and were first introduced as
an alternative to ACE-Is in patients who had an ACE-I
induced cough.
ACE-Is and ARBs are valuable BP-reducing agents in
CKD patients, are indicated if urinary albumin excretion
is elevated and are safe to combine with most other
BP-reducing agents. Clinically significant hyperkalemia
and reductions in GFR can occur in patients receiving
ACE-Is or ARBs, particularly in those who have renal-artery
stenosis or reduced intravascular volume, or when these
agents are used together with NSAIDs, COX-2 inhibitors,
or potassium-sparing diuretics. The use of these drugs in
women of child-bearing age should be balanced with the risk
of pregnancy since they are potentially teratogenic (see
Chapter 6).84,85
The sequential marketing of ACE-Is first (captopril in
1977) and ARBs later (losartan in 1995) has influenced the
design of RCTs involving these drug classes. The first large-
scale RCT of RAAS blockade in diabetes involved patients
with type 1 disease given captopril. By the time ARBs were
introduced, the benefits of ACE-Is (in CKD patients with
type 1 diabetes) were well established. Thus RCTs involving
ARBs generally targeted individuals with type 2 diabetes. This
has led to some bias in the evidence base underpinning
recommendations for using ACE-Is or ARBs in the treatment
of BP. There is no substantive evidence to suggest that ACE-Is
and ARBs differ in their ability to reduce BP in patients with
essential hypertension.86 In most health care settings, ACE-Is
are less expensive than ARBs, which may influence the choice
between an ACE-I or ARB.
The most prominent BP-related effects of the blockade of
angiotensin II by ACE-Is or ARBs are as follows:
K Generalized arterial vasodilatation, resulting in lower BP.
K Vasodilatation of the efferent and afferent glomerular
arterioles, particularly the efferent, resulting in decreased
intra-glomerular pressure and hence reduction in both
GFR and urine albumin excretion. This is believed to
result in some degree of long-term renoprotection, at
least in patients with albuminuria.87 On initiation of
therapy a reversible reduction in GFR of up to 30%
(accordingly a 30% increase in SCr concentration) has
been regarded as reasonably attributable to this physio-
logical mechanism. Greater reductions may indicate
underlying renal artery stenosis.1,88 It has been suggested
that in advanced CKD, cessation of RAAS blockade may
allow an increase in GFR of sufficient magnitude to delay
end-stage kidney failure.23 This concept is further
discussed in Chapter 8.
K Reduction in adrenal secretion of aldosterone. In about
50% of subjects prescribed ACE-Is or ARBs, aldosterone
production is restored to at least pre-treatment levels over
a period of months (a phenomenon termed aldosterone
breakthrough).89 This may explain the efficacy of
aldosterone antagonists in patients already taking an
ACE-I or ARB.
ACE-Is and ARBs may have other effects, including
inhibition of fibrosis and enhancement of vascular and
cardiac remodelling. Discussion of these effects, which may
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be of relevance to renoprotection, is beyond the scope of this
Guideline.
Dose considerations in CKD patients. Most available
ACE-Is have active moieties that are largely excreted in the
urine. Fosinopril and trandolapril are partially (in general,
approximately 50%) excreted by the liver, such that the blood
levels are less influenced by kidney failure than levels of other
ACE-Is which are predominantly excreted by the kidneys.
Since ACE-Is are generally titrated to achieve optimal clinical
effect, the mode of excretion is not regarded as a major factor
in dosing.76 If hyperkalemia occurs in CKD patients taking a
renal excreted ACE-I, possible interventions include dietary
advice, reducing the dose, switching to fosinopril or
trandolapril, or adding a potassium-losing diuretic.
All ARBs are substantially excreted by the liver, with the
proportion of drug elimination ranging from 40% (in the
case of candesartan) to 495% (in the case of irbesartan and
telmisartan). As with ACE-Is, the dose in ARBs is usually
adjusted according to clinical effect rather than kidney
function.76
ACE-Is and ARBs should be used with caution or even
avoided in certain CKD subgroups, particularly in
patients with bilateral renal-artery stenosis or with intravas-
cular fluid depletion, because of the risk of a large reduction
in GFR. The normal capacity of the kidney to auto-regulate
GFR in the face of fluctuations in BP is impaired in CKD
and further compromised by the use of ACE-Is or ARBs.
Hypotension (e.g., as a result of hypovolemia or sepsis) may
cause an acute decline in GFR in patients with CKD taking
ACE-Is or ARBs.90 Several case series have reported a high
risk of acute kidney injury in diabetic patients on an ACE-I
or ARB during sepsis91–93 and when they are used in
combination with NSAIDs94 or diuretics.95 Reducing the
dose or holding off on using ACE-Is or ARBs until recovery is
sensible in patients who develop inter-current illnesses
that lead to dehydration as a result of diarrhea, vomiting,
or high fever.
Indications for ACE-Is and ARBs. In this guideline,
ACE-Is and ARBs are recommended for specific groups of
CKD patients with increased urinary albumin excretion in
which context use of these agents may be associated with
better kidney96 and cardiovascular outcomes.97 In non-CKD
patients, these drugs are indicated for the treatment of heart
failure and for use soon after myocardial infarction, stroke,
and in patients with high cardiovascular risk.98–100
The Oregon Health Resources Commission reported in
2005 on the use of ACE-Is in essential hypertension. No
differences were found among various ACE-Is in terms of the
BP-lowering effect and serious complications which were
independent of gender, age, or African-American heritage.99
In 2006, the Commission reviewed the evidence for the use of
ARBs.100 It reported that there were no data to suggest that
any particular ARB was superior to another in the context of a
variety of clinical scenarios, including essential hypertension
and high cardiovascular risk; nor was there evidence of any
ARB being associated with a higher risk of serious complica-
tions or differences in efficacy or side effects regardless of age,
race, or gender. In reviewing studies specifically involving
patients with CKD, no important differences in the effect of
ARBs on BP or side effects were found.
Accordingly, ACE-Is or ARBs might be considered for use
in patients with CKD who have heart failure, recent
myocardial infarction, a history of stroke, or a high
cardiovascular risk. However, it is not possible to make any
recommendations for CKD patients in particular, since the
data are largely from studies of non-CKD patients. In
addition, because CKD patients are at higher risk of side
effects, particularly hyperkalemia and reduction in GFR, the
use of ACE-Is or ARBs may not have the same risk-to-benefit
ratio in CKD patients as in non-CKD populations.
Drug combinations. The antihypertensive and anti-
albuminuric effects of ACE-Is and ARBs are complemented
by dietary sodium restriction or administration of diure-
tics.63,65,66 ACE-Is and ARBs are therefore valuable adjuncts
to diuretics for the treatment of high BP and vice versa. Co-
administration of beta-blockers and calcium-channel block-
ers with ACE-Is or ARBs is also acceptable. One recent post
hoc analysis of a large trial involving hypertensive individuals
demonstrated that a combination of an ACE-I (benazepril)
and calcium antagonist (amlodipine) was superior to the
same ACE-I used with a diuretic (hydrochlorothiazide) in
slowing CKD progression.101
Patients given NSAIDs, COX-2 antagonists or potassium-
sparing diuretics can develop hyperkalemia if these drugs are
used in combination with ACE-Is or ARBs. The combination
of ACE-Is and/or ARBs with aldosterone-blocking antago-
nists is an area of current controversy that is covered in more
detail below and in Chapter 8.
Aldosterone antagonists. The aldosterone antagonist spiro-
lactone has been in use as a BP-lowering agent since the late
1950s. Prescribed as a diuretic in the treatment of edema and
resistant hypertension, it fell into disuse with the advent of
more powerful diuretics and antihypertensives. With the high
doses initially used (up to 300mg/day), spironolactone use
was associated with side effects, particularly those due to its
estrogen-like activity (gynecomastia and menstrual distur-
bances). Recognition that BP-lowering could be achieved
with much lower doses of spironolactone (12.5–50mg/day)
has led to renewed interest in aldosterone antagonists over
the past decade.102–105 As a result, eplerenone, a miner-
alocorticoid-receptor blocker without estrogen-like effects,
has been developed. In CKD, the major emphasis has been on
using aldosterone antagonists to reduce urine albumin levels
and as an adjunct to other antihypertensive agents in treating
resistant hypertension. Aldosterone antagonists are of proven
benefit in non-CKD patients with heart failure, including
heart failure after myocardial infarction. Because of the risk
of hyperkalemia and reduction in GFR, they should be used
with caution in CKD patients.
Dose considerations in CKD patients. Impaired renal
excretion of native drug or active metabolites of spirono-
lactone and eplerenone and an increased risk of hyperkalemia
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may limit their use in patients with CKD. Plasma potassium
levels and kidney function should be monitored closely
during the introduction of aldosterone antagonists and
during intercurrent illnesses, particularly those associated
with a risk of GFR reduction, as occurs with dehydration.
Indications for aldosterone antagonists. In patients
without CKD, aldosterone antagonists are recommended
for the treatment of severe cardiac failure that is resistant to
other therapies and for use after acute myocardial infarction
complicated by cardiac failure. These agents also have a place
in the management of essential hypertension that is resistant
to other therapies. It is unclear whether this information can
be extrapolated to CKD patients, particularly those with
advanced CKD in whom the risks associated with the use of
aldosterone antagonists, particularly of hyperkalemia, may be
increased.
In patients with CKD, aldosterone antagonists have been
shown to decrease urine albumin excretion when added to
ACE-I or ARB therapy. In the largest relevant RCT available
involving CKD patients with elevated urine albumin levels
and type 2 diabetes, 177 patients received eplerenone (either
50 or 100mg daily) and 91 patients received placebo.106 The
addition of eplerenone to enalapril (20mg/day) resulted in a
reduction in AERs of 40 to 50% by 12 weeks in the
eplerenone groups, but by o10% in the placebo group. The
greater reduction in AER in the CKD patients receiving an
aldosterone antagonist in addition to an ACE-I or ARB is
consistent with the findings of many smaller trials.103,107,108
Small reductions in GFR and systolic BP have also been
reported. Hyperkalemia is a risk, but may have been
mitigated by the concurrent use of a thiazide diuretic
according to the smaller studies. Thiazide diuretics, however,
were not used in the larger RCT cited above and the risk of
hyperkalemia was similar among participants receiving
enalapril alone and those receiving the combination of
eplerenone and enalapril in that trial.106 It is premature to
draw a definite conclusion as to whether aldosterone
antagonists—through their anti-albuminuric, anti-hyperten-
sive, or anti-fibrotic effects—reduce the rate of decline in
kidney function in the long term. This is an area for future
research.109,110
Drug combinations. Aldosterone antagonists are potas-
sium-sparing diuretics and thus may be combined with
thiazide or loop diuretics that enhance potassium loss in the
urine. Great care should be exercised when aldosterone
antagonists are combined with ACE-Is, ARBs, or other
potassium-sparing diuretics. There is little information regard-
ing the combination of aldosterone antagonists with NSAIDs
or COX-2 inhibitors, but as with ACE-Is and ARBs, caution is
warranted. Both spironolactone and eplerenone interact with
cytochrome P-450, but definitive information regarding any
effect on calcineurin inhibitors (CNIs) is not available. Caution
is also advised when aldosterone antagonists are combined with
other cytochrome P-450–metabolized agents such as verapamil.
Direct renin inhibitors. The first clinically available
DRI, aliskiren, was approved by the US Food and Drug
Administration (FDA) in 2007. It binds to renin, preventing
the conversion of angiotensin I to angiotensin II. Data
relevant to DRIs were not available at the time of publication
of the KDOQI Clinical Practice Guidelines on Hypertension
and Antihypertensives Agents in Chronic Kidney Disease in
2004.1
Dose considerations in CKD patients. The usual dose of
aliskiren is 150 to 300mg given once daily. The dose is not
modified according to kidney function. It has been reported
that cyclosporine administration increases the half-life of
aliskiren in healthy subjects.111
Indications for DRIs. Although approved by the US FDA
only for the treatment of hypertension, it is uncertain
whether the indications for DRIs will eventually be similar to
those of ACE-Is and ARBs.
There has been one large study of aliskiren in CKD
patients, in which the drug was used in combination with the
ARB losartan in patients who also had type 2 diabetes with
nephropathy.112 A total of 599 patients were randomized to
losartan, 100mg daily, either alone (control group) or plus
aliskiren—150mg daily for 3 months and then 300mg daily
for 3 months. The addition of the 300mg dose of aliskiren
reduced the urinary albumin/creatinine ratio (ACR) by 20%
as compared with the use of losartan alone. There were only
small differences in BP between the two groups, and no
differences between the rates of adverse or serious adverse
events. Given the limited data available, the place of DRIs in
the management of BP in CKD has yet to be determined.
Indeed another trial involving the use of DRI combined with
losartan in patients with diabetes and CKD has recently been
terminated early due to an increased risk of adverse events
and no evidence of benefit in the combination therapy group.
Early termination of the Aliskiren Trial in Type 2 Diabetes
Using Cardiovascular and Renal Disease Endpoints (ALTI-
TUDE) trial casts doubt on the future use of DRIs in
combination with ACE-Is or ARBs,113 and very recently the
US FDA has counselled against this combination.114
Diuretics
Salt and water retention are major factors contributing to
high BP in CKD patients and to morbidity and mortality
through systemic or pulmonary edema. Thus, diuretics
potentially have an important role in the control of
hypertension in this clinical setting. The pharmacology of
diuretics and indications for their use have recently been
reviewed.115 Given that most CKD patients will require
multiple drugs to control elevated BP, thiazides have a role,
especially since their only major drawback is a propensity to
induce or aggravate hyperglycemia and other features of the
metabolic syndrome.116
Thiazides. Of the currently available antihypertensive
agents, thiazides and thiazide-like diuretics are most often
used and have been assessed in many RCTs involving CKD
patients, either as the primary investigational agent or as an
add-on therapy. Their side-effect profile is well known and
their pharmacology has recently been extensively reviewed,115
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as has their role in treating hypertension.115,117,118 Although
salt and water excretion may initially account for their
antihypertensive effect, why they lower BP over the long term
is less well understood and may involve direct or indirect
vasodilator actions.115,119 The metabolic side effects (hyper-
glycemia, hyperuricemia, visceral adiposity) are also not
completely understood119 but should be considered in
patients at risk of metabolic syndrome.
There are 2 broad groups of thiazide-type diuretics:
thiazides whose names end in ‘thiazide,’ and thiazide-like
agents such as chlorthalidone and indapamide. In recent
years, the thiazide diuretics have been used in low doses in
treatment of hypertension (hydrochlororthizide 12.5 to
25mg, bendroflumethiazide 2.5mg daily). The valid compar-
ison is thus of low dose thiazide versus thiazide-like diuretic.
These regimens have been compared in the recent UK
National Institute for Health and Clinical Excellence (NICE)
guidelines on primary hypertension.117 There was limited
evidence of any differences in BP control, clinical outcomes
or cost-effectiveness. NICE recommended that in newly
treated primary hypertensives, the thiazide-like diuretics were
preferable to the thiazides, based on the larger volume of
evidence for efficacy. The relevance of these observations to
CKD patients is unclear.
Dose considerations in CKD patients. Although thiazides
are excreted by the kidney, no dose adjustment is recom-
mended in patients with reduced GFR. As the GFR falls below
about 30–50ml/min/1.73m2, the ability of thiazides to over-
come fluid retention is diminished, although their antihyper-
tensive benefit may be preserved, at least according to small,
short-term studies in humans.120 Most clinicians switch to a
loop diuretic in patients with CKD 4, particularly if the BP is
becoming resistant to therapy or edema becomes a problem.
Drug combinations. Thiazides are often one of the first
2 or 3 drugs used for BP lowering in CKD, particularly if
there is edema or if ACE-Is or ARBs have already been
prescribed. Thiazides are known to potentiate the effect of
other antihypertensive agents, particularly ACE-Is and
ARBs63,66 and may also reduce the risk of hyperkalemia.
The inclusion of thiazides in fixed-dose combinations with
other antihypertensives is convenient for patients and may
improve compliance.83
Loop diuretics. Furosemide (also called frusemide), bu-
metanide, torsemide and ethacrynic acid are the most
commonly used loop diuretics, with wide dose ranges and
differing pharmacodynamics. In primary hypertension they
are effective in the short term121 but less so than thiazides in
the long term.115 Loop diuretics are particularly useful when
treating edema and high BP in CKD 4–5 patients in addition
or as an alternative to thiazide diuretics.
Potassium-sparing diuretics. Triamterene and amiloride
are usually avoided in patients with CKD because of the risk
of hyperkalemia. They are less effective in reducing extra-
cellular fluid volume than thiazides or loop diuretics.
Aldosterone antagonists such as spironolactone and epler-
enone are discussed separately, above.
Beta-blockers
Beta-blockers are one of the most extensively investigated
class of agents, having been used to treat hypertension and
CVD for over 40 years. Although all beta-blockers are
effective at reducing BP, other issues may influence whether
they are appropriate in a given patient and which specific
drug is chosen, since beta-blockers vary widely in their
pharmacology.122–124 Specific attention should be paid to
beta-blocker accumulation in patients with advanced CKD
and to ensuring that the beta-blocker usage is appropriate in
targeting a patient’s co-morbidities.
Dose considerations in CKD patients. In patients with
CKD, the accumulation of beta-blockers or active metabolites
could exacerbate concentration-dependent side effects such
as bradycardic arrhythmias.123 Such accumulation occurs
with atenolol and bisoprolol, but not carvedilol, propranolol,
or metoprolol.123
Indications for beta-blockers. A consensus report based
on evidence reviewed by the Pharmaceutical Subcommittee
of the Oregon Health Resources Commission in 2008
gave an update of the indications for use of beta-blockers
in non-CKD patients.125 The subcommittee concluded
that although no particular beta-blocker had been shown
to be more effective in reducing BP or alleviating angina than
another, in cases of mild-to-moderate heart failure, biso-
prolol, carvedilol, and metoprolol succinate reduced mortal-
ity and in cases of severe heart failure, carvedilol and
metoprolol succinate reduced mortality. After a recent
myocardial infarction, acebutolol, carvedilol, metoprolol
tartrate, propranolol and timolol all reduced mortality. A
recent systematic review and meta-analysis of beta-blockers
in CKD126 endorsed the use of beta-blockers in CKD patients
with heart failure but did not provide any definitive
specific advice on the their efficacy in preventing mortality,
cardiovascular outcomes or renal disease progression in CKD
patients without heart failure.
Drug combinations. Beta-blockers have often been
combined with diuretics in RCTs and clinical practice.124,127
There are no theoretical reasons why beta-blockers should
not be combined with ACE-Is or ARBs.128 The combination
of atenolol or bisoprolol (which accumulate in CKD
patients) with bradycardia-inducing drugs such as non-
dihydropyridine calcium-channel blockers is not recom-
mended. The combination of lipophilic beta-blockers (which
cross the blood–brain barrier) with other centrally acting
drugs such as clonidine may lead to drowsiness or confusion,
particularly in the elderly. Again, the relevance of these data
to patients with CKD remains uncertain.
Calcium-channel blockers
Calcium-channel blockers are valuable BP-lowering agents
in CKD patients, but this class of drugs is very hetero-
geneous in several respects and the choice of the type of
agent used should take into account these differences as well
as co-morbidities and other medications the patient is
taking.
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The major subclasses are the dihydropyridines (e.g.,
amlodipine, nifedipine and lercanidipine), the non-dihydro-
pyridine benzothiazepines (e.g., diltiazem) and the phenyl-
alkylamines (e.g., verapamil).129 Dihydropyridines tend to be
more selective for vascular smooth muscle (vasodilatation)
with less action on the myocardium. Accordingly, the side
effects may include fluid retention and ankle edema, which
can be problematic in patients with CKD. Dizziness, head-
ache and redness in the face are also common side effects.
Non-dihydropyridines have direct effects on the myocar-
dium, including the sinoatrial and atrioventricular nodes and
reduce the heart rate and cardiac-muscle contraction.
Calcium-channel blockers also vary in their effects on
glomerular arterioles, reflecting differential blockage of T-
channel receptors (on the afferent and efferent arteriole)
versus L-channel receptors (predominantly on the afferent
arteriole). T-channel blockade leads to a reduction in intra-
glomerular pressure, and accordingly a fall in urine albumin
levels, while an increase in the urine albumin level can occur
with blockade of L-channel receptors. In general, dihydro-
pyridine calcium-channel blockers act on L-channel recep-
tors, hence have the effect of increasing urine albumin
excretion, whereas non-dihydropyridines tend not be asso-
ciated with this side effect.130 Later generation dihydropyr-
idines (e.g., manipine, cilnidipine) are less prone to
increasing albumin excretion and may even reduce it.
Dose considerations in CKD patients. Most calcium-
channel blockers do not accumulate in patients with
impaired kidney function, with the exception of nicardipine
and nimodipine. Accumulation of these agents may also be
due to reduced blood flow to the liver in the elderly.129
Caution is thus advised when using these two agents in
elderly patients with CKD.
Indications for calcium-channel blockers. Calcium-chan-
nel blockers are widely used in the treatment of hypertension,
angina, and supra-ventricular tachycardia. The Oregon
Health Resources Commission report on calcium-channel
blockers in 2005 concluded that there was no clear evidence
to differentiate the antihypertensive effects of one calcium-
channel blocker from another (inadequate evidence for
felodipine).131 Whether these observations can be translated
to the CKD population is uncertain.
It is wise to avoid dihydropyridine calcium channel
blockers in CKD patients with already increased urinary
albumin excretion, particularly if there is not concomitant
use of an ACE-I or ARB.132
Drug combinations. Fluid retention, seen particularly
with dihydropyridines, can be problematic in patients with
CKD, such that avoiding other vasodilators may be sensible.
The combination of non-dihydropyridines such as verapamil
and diltiazem with beta-blockers can lead to severe
bradycardia, particularly in patients with advanced CKD if
drugs such as atenolol and bisoprolol, (that accumulate in
CKD) are used.
Calcium-channel blockers, particularly non-dihydropyri-
dines, interfere with the metabolism and excretion of the
CNIs, cyclosporine and tacrolimus, as well as the mammalian
target of rapamycin (mTOR) inhibitors, sirolimus and
everolimus76 (Table 2). This is relevant to the treatment of
high BP in kidney-transplant recipients, but also in patients
with immune-mediated CKD requiring immunosuppression.
When such patients are prescribed non-dihydropyridine
calcium-channel blockers, careful monitoring of CNIs and
mTOR inhibitors blood levels is required if drugs or dosages
are changed. Some clinicians use non-dihydropyridine
calcium-channel blockers to increase CNI or mTOR inhibitor
blood levels and thus reduce cost, particularly in kidney-
transplant patients.
Centrally acting alpha-adrenergic agonists
Centrally acting alpha-agonists cause vasodilatation by
reducing sympathetic outflow from the brain.133,134 The main
agents in use are methyldopa, clonidine, and moxonidine.
Moxonidine was not widely available in 2004 and thus was
not reviewed for the KDOQI Clinical Practice Guidelines on
Hypertension and Antihypertensives Agents in Chronic Kidney
Disease.1 The use of this drug in essential hypertension was
extensively reviewed by Fenton at al. in 2006.133 Dosing of
centrally acting alpha-antagonists is limited by side effects, but
since they interact minimally with other antihypertensives or
immunosuppressants, they are valuable as adjunct therapy for
resistant hypertension in CKD patients.
Dose considerations in CKD patients. Doses of methyl-
dopa or clonidine are not generally reduced in patients with
impaired kidney function. Moxonidine is extensively excreted
by the kidney and accordingly it has been recommended that
the dosage (usually 200 to 400mg daily) should be reduced in
the presence of a low GFR.134 On the other hand, an RCT of
moxonidine, 300mg daily, or the calcium-channel blocker
nitrendipine, 20mg daily, added to an ACE-I or ARB plus
loop diuretic in 177 hypertensive CKD patients (GFR by the
Cockcroft–Gault equation, o30ml/min/1.73m2) indicated
that adverse events occurred in similar proportions of
patients treated with moxonidine (50 of 89 [56.2%]) and
nitrendipine (46 of 82, [56.1%]), as did those adverse events
possibly due to the study drug (moxonidine 28%, nitrendi-
pine 32%), suggesting that although side effects are common,
moxonidine can be used in advanced CKD.135 Common
Table 2 | Selected calcium-channel blockers
Class
Accumulate in
renal failure
Increase
CNI levels
Increase
sirolimus levels
Amlodipine D N Y —
Diltiazem B N Y Y
Felodipine D N — —
Isradipine D N — —
Lercanidipine D N — —
Nicardipine D Y Y Y
Nifedipine D N N —
Nimodipine — Y — —
Nisoldipine D N — —
Verapamil P N Y Y
B, non-dihydropyridine benzothiazepine; CNI, calcineurin inhibitor; D, Dihydropyri-
dine; N, No; P, phenylalkylamine; Y, Yes; —, no data.
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severe adverse events associated with moxonidine in this RCT
were gastrointestinal symptoms, dizziness, headache and
tiredness; all of which occurred in between 10 to 15% of the
patients receiving moxonidine.
Indications for centrally acting alpha-agonists. Since
alpha-agonists do not interact with other commonly used
antihypertensive agents, they are valuable as adjunctive
therapy for high BP in CKD patients already taking other
antihypertensive medications. Because of the side-effect
profile, however, caution is advised when using alpha-
agonists in the elderly, in patients with advanced CKD and
in those taking sedating drugs.
In one large study of non-CKD patients with advanced
heart failure, high-dose moxonidine use was associated with
increased mortality.136 How this relates to patients with CKD
is unclear. Avoidance is probably wise if overt heart failure is
present. Since clonidine can slow pulse rate, this drug should
be avoided if bradycardia or heart block is present.
Drug combinations. Combination of alpha-agonists with
thiazides is probably advantageous to reduce vasodilatation-
induced fluid retention. Combination with other antihyperten-
sive drugs is usually trouble-free, but caution is advised if the
agents have similar side effects. Interactions are not common
between alpha-agonists and CNIs or mTOR inhibitors.
Alpha-blockers
Alpha-adrenergic blockers selectively act to reduce BP by
causing peripheral vasodilatation. Prazosin, doxazosin, and
terazosin are the alpha-blockers most commonly used in
treatment of hypertension. Alpha-blockers are an adjunctive
treatment for elevated BP in CKD patients in whom ACE-Is,
ARBs, diuretics, calcium-channel blockers, and beta-blockers
have failed or are not tolerated. Alpha-blockers may also be
advantageous if symptoms of prostatic hypertrophy are present.
Dose considerations in CKD patients. Alpha-blockers do
not require dose modification in cases of kidney failure, since
they are excreted via the liver.4
Indications for alpha-blockers. Alpha-blockers reduce the
symptoms of benign prostatic hyperplasia, which may be a
co-morbidity to consider in older men with CKD. In general,
alpha-blockers are not considered a first-line choice because
of the common side effects of postural hypotension,
tachycardia and headache. They should be commenced at a
low dosage to avoid a first-dose hypotensive reaction.
Drug combinations. There are few data available about
alpha-blocker combinations with other BP lowering drugs.
Vasodilatation can lead to peripheral edema, so diuretics are
commonly combined with alpha-blockers, although the
efficacy of this maneuver has not been studied. Alternatively,
a non-selective beta-blocker can be used.
Direct vasodilators
Hydralazine and minoxidil both act by directly causing
vascular smooth-muscle relaxation and hence vasodilatation.
There have been no important changes to our understanding
of these drugs since the publication of the KDOQI Clinical
Practice Guidelines on Hypertension and Antihypertensives
Agents in Chronic Kidney Disease in 2004.1
Dose considerations in CKD patients. Hydralazine and
minoxidil do not require dose adjustment in patients with
impaired kidney function.4
Indications for direct vasodilators. Hydralazine has little
value in the management of chronically elevated BP in CKD,
although it is sometimes used as a parenteral hypotensive
agent. Minoxidil is generally used in patients with very
resistant hypertension and thus may be helpful in patients
with CKD. However, its side effects (e.g., severe fluid
retention, headache, tachycardia, hirsutism, and pericardial
effusion) limit its use to the most resistant cases.
Drug combinations. Because of the side effects of fluid
retention and tachycardia, direct vasodilators (especially
minoxidil) are usually combined with a beta-blocker and
loop diuretic.
RESEARCH RECOMMENDATIONS
K Salt restriction appears to be a very promising method of
reducing BP and the risk of progressive kidney disease
and cardiovascular events. Therefore, large scale RCTs
assessing the impact of this intervention on these patient-
level outcomes are required. Patients with CKD should be
included in these trials, given the potential for differences
in the risks and benefits of reduced salt intake in these
individuals.
K RCTs should be undertaken to evaluate the benefit of
weight loss at different stages of CKD.
K RCTs should be undertaken in CKD with and without
elevated albumin excretion levels comparing various
combinations of RAAS blocking drugs.
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